Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Inclusion Criteria:

- Diagnosis of moderate to severe AS with prior documented radiologic evidence (X-ray)
fulfilling the Modified New York criteria for AS (1984)

- Have active AS defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
≥4 and the spinal pain (back pain) score ≥4 on a numeric rating scale (NRS)

- Participants should have been on nonsteroidal anti-inflammatory drugs (NSAIDs) with
an inadequate response

- Participants who are regularly taking NSAIDs or cyclooxygenase-2 (COX-2) inhibitors
as part of their AS therapy are required to be on a stable dose

- Participants who have been on a tumor necrosis factor alpha (TNF) inhibitor (not more
than one) must have experienced an inadequate response

- Total duration of prior therapy (NSAIDs and/or adequate physical therapy) should be
at least 12 weeks

- Men must agree to use a reliable method of birth control or remain abstinent during
the study

- Women must agree to use reliable birth control or remain abstinent during the study
and for at least 12 weeks after stopping treatment

Exclusion Criteria:

- Participants with a total ankylosis of the spine

- Prior or current treatment with adalimumab

- Participants previously treated with any biological or other immunomodulating agents
except for those targeting TNF

- Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other
than ankylosing spondylitis

- Have participated in any study with interleukin 17 (IL-17) antagonists, including
ixekizumab

- Serious disorder or illness other than ankylosing spondylitis

- Serious infection within the last 3 months

- Breastfeeding or nursing (lactating) women